OptimizeRx Corp. (NASDAQ:OPRX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

OptimizeRx Corp. (NASDAQ:OPRX) has been assigned an average rating of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $13.4286.

OPRX has been the subject of several recent analyst reports. B. Riley Financial cut their price target on OptimizeRx from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Weiss Ratings lowered OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday. Stephens cut their price target on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating for the company in a research note on Wednesday. Zacks Research lowered OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 4th. Finally, Roth Mkm cut their price target on OptimizeRx from $32.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, March 6th.

Hedge Funds Weigh In On OptimizeRx

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of OptimizeRx by 15.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,059,109 shares of the company’s stock valued at $21,712,000 after purchasing an additional 138,224 shares in the last quarter. Royce & Associates LP increased its stake in shares of OptimizeRx by 0.7% in the 4th quarter. Royce & Associates LP now owns 682,030 shares of the company’s stock valued at $8,362,000 after purchasing an additional 4,700 shares in the last quarter. Kennedy Capital Management LLC boosted its holdings in OptimizeRx by 42.8% in the 3rd quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock worth $13,836,000 after buying an additional 202,446 shares during the last quarter. Rice Hall James & Associates LLC boosted its holdings in OptimizeRx by 1.9% in the 1st quarter. Rice Hall James & Associates LLC now owns 601,921 shares of the company’s stock worth $3,780,000 after buying an additional 11,247 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in OptimizeRx by 22.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company’s stock worth $3,540,000 after buying an additional 102,661 shares during the last quarter. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Stock Performance

NASDAQ OPRX opened at $5.21 on Monday. The stock has a 50-day simple moving average of $6.44 and a two-hundred day simple moving average of $10.61. The firm has a market capitalization of $97.74 million, a P/E ratio of 14.89 and a beta of 1.19. OptimizeRx has a fifty-two week low of $4.57 and a fifty-two week high of $22.25. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.37 and a current ratio of 5.37.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. The business had revenue of $19.84 million during the quarter, compared to analyst estimates of $18.74 million. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%. On average, equities analysts forecast that OptimizeRx will post 0.5 earnings per share for the current year.

OptimizeRx declared that its Board of Directors has authorized a stock buyback plan on Thursday, March 5th that allows the company to repurchase $10.00 million in shares. This repurchase authorization allows the company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.